| human | Q5 |
| P496 | ORCID iD | 0000-0003-3947-4126 |
| P735 | given name | Elizabeth | Q385468 |
| Elizabeth | Q385468 | ||
| P106 | occupation | researcher | Q1650915 |
| Q68177598 | 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial |
| Q90034592 | A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease |
| Q38766349 | A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells |
| Q91844297 | A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation |
| Q46910451 | A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts |
| Q71032334 | A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies |
| Q33964687 | A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease |
| Q40787128 | A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant |
| Q33500869 | A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. |
| Q77293827 | A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients |
| Q47853810 | A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results |
| Q34149903 | A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma |
| Q38376648 | A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas |
| Q39516905 | A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy |
| Q39207628 | A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. |
| Q37677431 | ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity |
| Q33877778 | AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth |
| Q83336977 | AML-loaded DC generate Th1-type cellular immune responses in vitro |
| Q94145983 | ATIM-10. A PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS CMV-SPECIFIC CYTOTOXIC T CELLS (CMV-TC) FOR GLIOBLASTOMA: DOSE ESCALATION AND CORRELATIVE RESULTS |
| Q35522878 | Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes |
| Q60458211 | Acute Myeloid Leukemia Cells Acquire Stem Cell Features in the Bone Marrow Microenvironment |
| Q28372680 | Acute encephalopathy: a new toxicity associated with high-dose paclitaxel |
| Q70649457 | Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine |
| Q74082637 | Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation |
| Q33566426 | Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience |
| Q29393780 | Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes |
| Q35863989 | Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation |
| Q87026492 | Allele-level HLA cord blood matching matters |
| Q57281351 | Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy |
| Q30277009 | Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia |
| Q64880151 | Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study. |
| Q36865042 | Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution |
| Q57293461 | Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia |
| Q47613943 | American Society for Blood and Marrow Transplantation guidelines for training |
| Q72454726 | Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support |
| Q35034803 | Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. |
| Q47120905 | Are 2 cords better than 1? |
| Q48864852 | Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. |
| Q110596864 | Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement |
| Q86511304 | Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement |
| Q33828956 | Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. |
| Q33769684 | Autologous stem-cell transplantation for solid tumors in adults |
| Q81922026 | Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study |
| Q40944156 | Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System |
| Q36408968 | Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size |
| Q36115699 | Better allele-level matching improves transplant-related mortality after double cord blood transplantation. |
| Q71639942 | Bone marrow involvement by lobular carcinoma of the breast cannot be identified reliably by routine histological examination alone |
| Q41033249 | Bone marrow metastases |
| Q103747715 | Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway |
| Q39434165 | Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience |
| Q94571736 | CAR-Transduced Natural Killer Cells. Reply |
| Q26830526 | CARs in chronic lymphocytic leukemia -- ready to drive |
| Q74579222 | CD19 selection improves the sensitivity of B cell lymphoma detection |
| Q38552467 | CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields |
| Q64104503 | CD34 cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking |
| Q41893896 | CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma |
| Q35776868 | CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo |
| Q52641917 | Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. |
| Q73803736 | Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer |
| Q114001207 | Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma |
| Q40627799 | Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients |
| Q37673349 | Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients |
| Q100302876 | Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions |
| Q95942088 | Chimeric Antigen Receptor T-cell Therapy Toxicities |
| Q97084597 | Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors? |
| Q37469199 | Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity |
| Q47681829 | Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. |
| Q38361826 | Chimeric antigen receptor T-cell therapy for ALL. |
| Q37804595 | Chronic Lymphocytic Leukemia: New Concepts for Future Therapy |
| Q90702511 | Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation |
| Q98614690 | Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma |
| Q36682812 | Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood |
| Q40400155 | Clinical applications of filgrastim and stem cell factor in vivo and in vitro |
| Q97518149 | Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma |
| Q92052674 | Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Tran |
| Q39212390 | Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results |
| Q35057041 | Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation |
| Q37140698 | Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. |
| Q33488166 | Comparative assays of megakaryocyte progenitors in CD34+ peripheral blood progenitor cell fractions |
| Q91031901 | Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens |
| Q50220250 | Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products: The automated Sepax system versus the manual Ficoll method |
| Q34601968 | Concise review: umbilical cord blood transplantation: past, present, and future |
| Q46412794 | Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas |
| Q37026763 | Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment |
| Q46916856 | Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chem |
| Q90699179 | Cord Blood Expansion: A Clinical Advance |
| Q26771337 | Cord Blood as a Source of Natural Killer Cells |
| Q47821811 | Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. |
| Q26822376 | Cord blood graft engineering |
| Q42428834 | Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. |
| Q42071734 | Cord blood stem cell therapy for acquired immune deficiency syndrome. |
| Q37247837 | Cord-blood engraftment with ex vivo mesenchymal-cell coculture |
| Q81676895 | Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients |
| Q57128911 | Current and future status of stem cell expansion |
| Q96832692 | Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia |
| Q40282393 | Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning |
| Q53088109 | Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. |
| Q114012477 | Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation |
| Q33404690 | De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination |
| Q46594783 | Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells. |
| Q36447936 | Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing |
| Q36380485 | Dendritic cell immunotherapy for the treatment of neoplastic disease |
| Q45859148 | Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals |
| Q33780277 | Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation |
| Q68520918 | Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology |
| Q67937564 | Detection of minimal residual breast cancer in bone marrow |
| Q96825382 | Development and validation of a risk assessment tool for BKPyV Replication in Allogeneic Stem cell Transplant Recipients |
| Q45889149 | Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model |
| Q72707006 | Dissemination and commercialization of hematopoietic progenitor cell transplantation |
| Q52653312 | Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. |
| Q87007715 | Does plerixafor destroy the hematopoietic progenitor cell/mesenchymal stromal cell niche? |
| Q58572537 | Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation |
| Q36667913 | Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease |
| Q37142892 | Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation |
| Q37192391 | Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. |
| Q46946456 | Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. |
| Q53315058 | Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. |
| Q30415126 | Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia |
| Q49968719 | Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia |
| Q77379006 | Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery |
| Q63446345 | Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic Reconstitution after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation |
| Q35177492 | Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation |
| Q49546513 | Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion |
| Q41664885 | Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres |
| Q69516182 | Elimination of malignant clonogenic breast cancer cells from human bone marrow |
| Q53567287 | Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. |
| Q102371441 | Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model |
| Q33622648 | Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement |
| Q35583385 | Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation |
| Q39408704 | Engineering Natural Killer Cells for Cancer Immunotherapy |
| Q33766995 | Engineering cord blood to improve engraftment after cord blood transplant |
| Q52193986 | Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. |
| Q37902269 | Evaluation and management of BK virus-associated nephropathy following allogeneic hematopoietic cell transplantation. |
| Q33749652 | Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells |
| Q46516809 | Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy |
| Q73794146 | Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation |
| Q49630800 | Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease |
| Q50645498 | Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. |
| Q74293926 | Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential |
| Q73119243 | Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer |
| Q51982574 | Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. |
| Q37607979 | Ex vivo expansion of cord blood |
| Q51359131 | Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. |
| Q33500499 | Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. |
| Q33367674 | Ex vivo expansion of umbilical cord blood |
| Q37788414 | Ex vivo expansion of umbilical cord blood for transplantation |
| Q35126283 | Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo |
| Q39529592 | Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma |
| Q77799893 | Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer |
| Q58763857 | Excellent Outcomes After Umbilical Cord Blood Transplantation Using a Centralized Cord Blood Registry |
| Q36305254 | Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus |
| Q35486077 | Expression of a surface antigen (MA6) by peripheral blood CD34+ cells is correlated with improved platelet engraftment and may explain delayed platelet engraftment following cord blood transplantation |
| Q33369676 | Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. |
| Q46884477 | Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? |
| Q37154179 | Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion |
| Q35962339 | Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. |
| Q42719240 | FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. |
| Q36004664 | Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries |
| Q82419617 | Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells |
| Q64077473 | Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study |
| Q83302820 | Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma |
| Q58565569 | Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial |
| Q37738997 | Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients |
| Q34545908 | Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia |
| Q41770362 | Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. |
| Q91061698 | Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes |
| Q45896384 | Fucosylation enhances activity of cytotoxic T lymphocytes against breast cancer |
| Q34375340 | Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment |
| Q37334642 | Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes |
| Q53570839 | Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by alpha 4 beta 1 integrin/vascular cell adhesion molecule-1 interaction. |
| Q41019475 | Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support |
| Q112297775 | GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells |
| Q40075321 | Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma |
| Q34575857 | Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results |
| Q36702752 | General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation |
| Q55386177 | Generation and testing of clinical-grade exosomes for pancreatic cancer. |
| Q34531834 | Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. |
| Q100387970 | Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy |
| Q112293407 | Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy |
| Q34635978 | Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant |
| Q36605814 | Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application |
| Q91997111 | Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses; results from a Phase I/II trial |
| Q52718618 | Graft Loss Attributed to Possible Transfusion-Transmitted Ehrlichiosis Following Cord Blood Stem Cell Transplant. |
| Q80459147 | Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier |
| Q73375232 | Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia |
| Q98181877 | Guidelines for Cord Blood Unit Selection |
| Q47447695 | Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. |
| Q52803378 | HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. |
| Q53081137 | HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. |
| Q85056137 | HLA matching of CB: it's complicated |
| Q91228087 | HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant |
| Q36999109 | Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial |
| Q47973564 | Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome |
| Q96820734 | Haploidentical Transplants for Patients with Graft Failure After the First Allograft |
| Q96958854 | Haploidentical Transplants for Patients with Relapse After the First Allograft |
| Q90923536 | Harmonizing Immune Effector Toxicity Reporting |
| Q38839367 | Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China |
| Q36295174 | Hematopoietic cell transplantation with cord blood for cure of HIV infections |
| Q41896967 | Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit |
| Q34302673 | Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy |
| Q33952830 | Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type |
| Q35073502 | High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation |
| Q68362738 | High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer |
| Q28330987 | High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity |
| Q51186226 | High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. |
| Q70736024 | High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer |
| Q34007823 | High-dose chemotherapy for breast cancer. |
| Q35742747 | High-dose chemotherapy for breast cancer: is another look warranted? |
| Q37521557 | High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? |
| Q41479753 | High-dose chemotherapy for the treatment of breast and ovarian cancer. |
| Q74627226 | High-dose chemotherapy in gynecologic malignancies |
| Q41194408 | High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results |
| Q40978407 | High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. |
| Q74545928 | High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer |
| Q74015715 | High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes |
| Q82832693 | High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later? |
| Q70211550 | High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer |
| Q63446395 | High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support |
| Q33566475 | High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies |
| Q71059764 | High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial |
| Q40661350 | High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors |
| Q78247747 | High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy |
| Q46464393 | Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease |
| Q34012519 | Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action |
| Q41049735 | IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation |
| Q47875518 | Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway |
| Q33615123 | Identification and frequency of CCR5Δ32/Δ32 HIV-resistant cord blood units from Houston area hospitals. |
| Q34057048 | Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. |
| Q90820404 | Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity |
| Q28740879 | Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model |
| Q37395931 | Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography |
| Q34408371 | Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support |
| Q70187160 | Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation |
| Q68719582 | Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation |
| Q91581908 | Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma |
| Q50494816 | Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes |
| Q96124310 | Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia |
| Q27487855 | Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies |
| Q36894993 | Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. |
| Q36794125 | Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations |
| Q34115051 | Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. |
| Q38778109 | Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. |
| Q35157385 | Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma |
| Q35837709 | Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis |
| Q35060682 | Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. |
| Q37785538 | Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood |
| Q77920822 | Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone |
| Q73067842 | Increased expansion and differentiation of cord blood products using a two-step expansion culture |
| Q33905443 | Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time |
| Q46595263 | Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. |
| Q79836903 | Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005 |
| Q35824950 | Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation |
| Q35988657 | Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. |
| Q37263151 | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study |
| Q45968380 | Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. |
| Q43848085 | Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft |
| Q33449349 | Intensive single-agent mitoxantrone for metastatic breast cancer |
| Q35136563 | Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL |
| Q33652742 | Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. |
| Q34449885 | Is there an expiration date for a cord blood unit in storage? |
| Q40401612 | Isolation of CD34-positive hematopoietic progenitor cells |
| Q38817168 | Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. |
| Q46105174 | KIR gene haplotype: an independent predictor of clinical outcome in MDS patients |
| Q39140025 | Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients |
| Q97894286 | Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells |
| Q40493612 | Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant |
| Q35812103 | Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation |
| Q33558780 | Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia |
| Q39632454 | Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. |
| Q47719805 | Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy |
| Q33915980 | Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes |
| Q40291708 | Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival |
| Q35994849 | Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis |
| Q92802576 | Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas |
| Q33864607 | Low rate of infusional toxicity after expanded cord blood transplantation. |
| Q33861150 | Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia |
| Q34510349 | Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation |
| Q56929047 | Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy |
| Q60458203 | Mesenchymal Stem Cells Differentiate into Osteoblasts in the Presence of AML Cells through Up-regulation of RUNX2 and Induce Chemo-resistance |
| Q92735596 | Mesenchymal stem cell-derived exosomes for clinical use |
| Q37247846 | Mesenchymal stem cells in ex vivo cord blood expansion |
| Q80486507 | Microbial contamination of hematopoietic progenitor cell products: clinical outcome |
| Q93154136 | Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells |
| Q99622927 | Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids |
| Q36157233 | Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. |
| Q33704413 | Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics |
| Q36962653 | Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation |
| Q42380473 | Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells |
| Q52191082 | Multilineage engraftment in NOD/LtSz-scid/scid mice from mobilized human CD34+ peripheral blood progenitor cells. |
| Q53384604 | Mycobacterium tuberculosis infection: a rare late complication after cord blood hematopoietic SCT. |
| Q92859338 | Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial |
| Q28321657 | Myocardial ischemia associated with high-dose carmustine infusion |
| Q84585430 | NK antibody therapy: KIR-ative intent |
| Q49238507 | New and emerging therapies for acute and chronic graft versus host disease |
| Q72096735 | New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation |
| Q38289909 | Non-fucosylated CB CD34+ cells represent a good target for enforced fucosylation to improve engraftment following cord blood transplantation |
| Q41985161 | Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells |
| Q44253909 | Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia |
| Q37602885 | Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. |
| Q77356558 | Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea |
| Q37800641 | Novel Cord Blood Transplant Therapies |
| Q90096667 | Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation |
| Q26772216 | Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials |
| Q80455355 | Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity |
| Q34505185 | Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. |
| Q44836524 | Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. |
| Q73072005 | Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support |
| Q38747929 | Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies |
| Q41275233 | Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells |
| Q35848756 | Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells |
| Q45402381 | Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection |
| Q92279764 | Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis |
| Q38780843 | Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. |
| Q40765042 | Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation |
| Q35563832 | Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure |
| Q39424810 | Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. |
| Q85241544 | Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia |
| Q42974699 | Overcoming the barriers to umbilical cord blood transplantation |
| Q37412238 | PET imaging of T cells derived from umbilical cord blood |
| Q39631989 | PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. |
| Q71976434 | Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience |
| Q48362201 | Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. |
| Q53710257 | Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. |
| Q41385479 | Peripheral blood stem cell harvesting and CD34-positive cell selection. |
| Q72990412 | Peripheral blood stem cell transplantation in breast cancer |
| Q41360578 | Peripheral blood stem cells for autografting |
| Q40859809 | Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer |
| Q79557465 | Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule |
| Q40073076 | Phase 1 clinical trial using mbIL21 ex-vivo expanded donor-derived NK cells after haploidentical transplantation |
| Q46423850 | Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies |
| Q38907104 | Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma |
| Q90172203 | Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma |
| Q80502490 | Phase I trial of parathyroid hormone to facilitate stem cell mobilization |
| Q37217432 | Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells |
| Q46909610 | Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome |
| Q38895415 | Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma |
| Q36779819 | Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. |
| Q87948736 | Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma |
| Q45144616 | Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer |
| Q80066587 | Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies |
| Q78074768 | Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease |
| Q36395129 | Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. |
| Q35171198 | Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations |
| Q73267491 | Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia |
| Q40445423 | Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients |
| Q71608163 | Positive selection of CD34+ hematopoietic progenitor cells for transplantation |
| Q57649369 | Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant |
| Q33764825 | Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation |
| Q89994509 | Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors |
| Q46690864 | Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine |
| Q39474999 | Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia |
| Q64949444 | Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. |
| Q95940680 | Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy |
| Q121283204 | Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART) |
| Q48686679 | Prognostic Index for Critically Ill Allogeneic Transplantation Patients. |
| Q80422583 | Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant |
| Q51990914 | Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. |
| Q36610892 | Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy |
| Q33743728 | Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support |
| Q77579151 | Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer |
| Q47589921 | Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support |
| Q81375260 | Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer |
| Q80997142 | Progress in dendritic cell immunotherapy: elucidating the enigma of Th-1 polarization |
| Q38285256 | Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective |
| Q26801269 | Progress toward curing HIV infection with hematopoietic cell transplantation |
| Q40562696 | Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma |
| Q28741513 | Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104 |
| Q34666851 | Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study |
| Q46378871 | Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N |
| Q92191062 | Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation |
| Q40883895 | Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia |
| Q35281265 | Purging of autologous bone marrow for transplantation: the protection and selection of the hematopoietic progenitor cell |
| Q46666404 | Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. |
| Q102981188 | RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine |
| Q49919531 | Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. |
| Q51660568 | Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. |
| Q90745772 | Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease |
| Q37723478 | Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance |
| Q69916369 | Recombinant human granulocyte-macrophage colony-stimulating factor produces fever |
| Q40479359 | Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. |
| Q36713904 | Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system |
| Q90372460 | Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS |
| Q33841389 | Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. |
| Q36149287 | Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment |
| Q34292984 | Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD |
| Q40396505 | Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation |
| Q53728604 | Release of tumor cells from bone marrow. |
| Q44057573 | Renal dysfunction in allogeneic hematopoietic cell transplantation |
| Q71690285 | Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer |
| Q35226501 | Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU |
| Q57758601 | Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation |
| Q43272332 | Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation |
| Q52323976 | Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. |
| Q35129216 | Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement |
| Q80387253 | Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies |
| Q52588202 | Role of MSC-derived galectin 3 in the AML microenvironment. |
| Q40831567 | Role of autotransplantation in treatment of other solid tumors. |
| Q94404770 | STEM-02. CHARACTERIZATION OF PATIENT-DERIVED BONE MARROW MESENCHYMAL STEM CELLS AS VIRUS CARRIERS FOR THE TREATMENT OF GLIOBLASTOMA |
| Q74314037 | Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation |
| Q100549860 | Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma |
| Q91774706 | Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients |
| Q38357127 | Shifting paradigms in the treatment of chronic lymphocytic leukemia |
| Q87994535 | Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma |
| Q89893024 | Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes |
| Q35129248 | Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. |
| Q104495067 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events |
| Q37097120 | Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. |
| Q24598792 | Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients |
| Q41644822 | Stem cell isolation |
| Q35887819 | Stem-cell transplantation for the treatment of advanced solid tumors |
| Q35550596 | Steroid-Refractory Acute GVHD: Predictors and Outcomes. |
| Q83275695 | Strategies for widening the use of cord blood in hematopoietic stem cell transplantation |
| Q42160266 | Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells |
| Q35068768 | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins |
| Q40894815 | Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients |
| Q41656484 | Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer |
| Q46916859 | Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation |
| Q99236449 | Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells |
| Q37176537 | Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens |
| Q57183589 | The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients |
| Q49565011 | The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide |
| Q68840479 | The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer |
| Q52689883 | The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. |
| Q92110124 | The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden |
| Q36772346 | The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia |
| Q41911583 | The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation |
| Q41688221 | The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation |
| Q36007787 | The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. |
| Q45125131 | The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy |
| Q68513286 | The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation |
| Q42654804 | Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease |
| Q33633262 | Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood |
| Q52732430 | Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. |
| Q27331909 | Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking |
| Q33374662 | Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment |
| Q40955853 | Transplantation of CD34+ hematopoietic progenitor cells |
| Q71649182 | Transplantation of CD34+Hematopoietic Progenitor Cells* |
| Q71604247 | Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment |
| Q74596740 | Transplantation of ex vivo expanded cord blood |
| Q33861192 | Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial |
| Q80568655 | Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation |
| Q36967029 | Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia |
| Q48229122 | Treg adoptive therapy: is more better? |
| Q49291505 | Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling |
| Q38514503 | Umbilical cord blood graft engineering: challenges and opportunities. |
| Q83422600 | Umbilical cord blood transplantation |
| Q38066870 | Umbilical cord blood transplantation: a maturing technology |
| Q36218983 | Umbilical cord blood-derived cells for tissue repair |
| Q91397936 | Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients |
| Q33841417 | Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission |
| Q79108424 | Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant |
| Q89548367 | Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors |
| Q71475868 | Use of amifostine in bone marrow purging |
| Q36871982 | Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients |
| Q36660672 | Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. |
| Q35485832 | p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. |
| Q30496580 | piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies |
Search more.